Dr. Melinda Mushonga

Clinical Oncologist| Equity in breast cancer care - Thou shall not tire! | In God we trust 🌸🌸

[Dr. Melinda Mushonga @MelMushonga]

Medical Tourism for Cancer Treatment in Africa: What We Found in our recent study across Africa, by @HamidMD10 https://t.co/A5X6jHR348

[Dr. Melinda Mushonga @MelMushonga]

@AGovindarajanMD @JCO_ASCO @cityofhope @COHMedOnc Thank you for sharing your experience,

[Dr. Melinda Mushonga @MelMushonga]

ADRIATIC -22.9% Radiation pneumonitis Durva arm Vs 23.4% placebo arm
LAURA- Orsi arm 48% RP Vs 38 %, retro series @Sunnybrook @MDAndersonNews late onset RP in pts receiving Durva . Preventative strategies for RP needed to support Laura Trial.

[Dr. Melinda Mushonga @MelMushonga]

@GirardWellness @pashtoonkasi @ASCO @ALLIANCE_org @OncoAlert Pt selection is key, there are patients in real practice who do well

[Dr. Melinda Mushonga @MelMushonga]

@pashtoonkasi @ntizimira @ASCO @ALLIANCE_org @OncoAlert How was “extensive “ quantified and OLM defined ?

[Dr. Melinda Mushonga @MelMushonga]

@bin_abeid @SalemGIOncDoc @OncoAlert @HamidMD10 Almost a 30% difference in treatment completion rates . Much less patients completed the CROSS protocol compared to the initial CROSS trial. Looking forward to full manuscript for more context and Rad Onc perspectives.

[Dr. Melinda Mushonga @MelMushonga]

@runciecwc @nazik_hammad @SullivanProf @OphiraG @darioT_ @ASCO @jrgralow @uicc @ntizimira @stage4kelly @TheLancetOncol @m_mutebi One of @AORTIC_AFRICA #ASCO24 highlights . We need to do better regarding war and conflict in Africa

[Dr. Melinda Mushonga @MelMushonga]

Proud moment, Zimbabwe one of the sites for AORTIC led first clinical trial ⁦@ntokozo_nndlovu⁩ ⁦@AORTIC_AFRICA⁩ ⁦@AnaNyakabau⁩ ⁦@QueensGlobalOnc⁩ ⁦@m_mutebi⁩ ⁦@nazik_hammad⁩

[Dr. Melinda Mushonga @MelMushonga]

@safaviaa @Mat_Guc @CJTsaiMDPhD Characterization of OMD is vital for OMD/RT trials ( particularly ablative doses)

[Dr. Melinda Mushonga @MelMushonga]

@CJTsaiMDPhD @NRGonc @rweichselbaum An oligo progression and oligo persistent cohort perhaps , 85% had a line systemic therapy prior, upto 25 Mets at baseline, a lot of nuances to dissect ,

[Dr. Melinda Mushonga @MelMushonga]

My research is available on @ResearchGate: https://t.co/uA0tDjOBXE

[Dr. Melinda Mushonga @MelMushonga]

@DrewMoghanaki Thanks for sharing !

[Dr. Melinda Mushonga @MelMushonga]

@safaviaa @IJROBP @ASTRO_org @drdavidpalma @LHSCCanada @MeredithGiulia1 @RadMedPM @UofTDRO @TekatliHilal @finn_corinne @Mat_Guc @DrAlexLouie Great read Amir! Well done

[Dr. Melinda Mushonga @MelMushonga]

@weeloonong @ASCO @DrAndrewLoblaw @Sunnybrook @UofTDRO Congrats Wee!

[Dr. Melinda Mushonga @MelMushonga]

@JablonskaPaola @AvipsaDas11 @RadMedPM @OncoRT_HUN Great work on this editorial Paola!

[Dr. Melinda Mushonga @MelMushonga]

@AggarwalOnc Congratulations!

[Dr. Melinda Mushonga @MelMushonga]

@DrAlexLouie @IASLC @_ShankarSiva @fifimcdrmh @finn_corinne @JoeChangMD @AndrearicFili @DrBezjakRO @pablomunozsch @HoudaBahig @przybyszmd Congratulations Alex!

[Dr. Melinda Mushonga @MelMushonga]

@SahgalArjun @ISRSy Informative , great read

[Dr. Melinda Mushonga @MelMushonga]

@Waynemanana Congratulations doc!

[Dr. Melinda Mushonga @MelMushonga]

@Ramesh_Pandey_ @TekatliHilal 12% seems high , had to read through manuscript , it’s unclear how its presented in results section Vs discussion. Agree with authors conclusion- longer f/u data needed ,